Document Detail


Pulmonary structural maturation and pulmonary artery remodeling after reversible fetal ovine tracheal occlusion in diaphragmatic hernia.
MedLine Citation:
PMID:  11329579     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Congenital diaphragmatic hernia (CDH) is associated with thickened pulmonary arteries (PA) contributing to pulmonary hypertension. In the current study, the effects of antenatal glucocorticoids and reversible tracheal occlusion (TO) on PA structure were assessed in a hypoplastic lung model. METHODS: A left-sided CDH was created in fetal lambs at 80 days gestation, TO at 108 days, and release of the occlusion (TR) at 129 days. All were given 1 dose of maternal glucocorticoids at 135 days. At 136 days (term, 145 days), the fetus was delivered by cesarian section. CDH (n = 7), CDH + TO (n = 6), CDH + TO + TR (n = 6), and unoperated twin controls (n = 16) were compared. Outcome measurements were (1) lung growth, represented by lung weight to body weight ratio (LW/BW), (2) lung structural maturation, which is inversely proportional to mean terminal bronchiole density (MTBD), (3) PA medial and adventitial areas (square micrometers), (4) lung capillary load, which is the ratio of vessel surface area (SA) to tissue SA ratio. RESULTS: CDH lungs were hypoplastic with a low LW/BW and high MTBD. The small PAs (<75 microm) of CDH had an increased medial area, indicating increased muscle mass and an increased adventitial area. CDH + TO +/- TR increased LW/BW and achieved normal structural lung maturity with a low MTBD. Only CDH + TO thinned the PA medial area closer to control values. The adventitial area remained thick in CDH +/- TO +/- TR when compared with controls. All 4 groups had similar capillary load. CONCLUSIONS: TO may be especially important for PA remodeling in the latter part of gestation, because TR 1 week before delivery prevents thinning of the small PAs in CDH. The shaping achieved by TO in terms of lung growth, structural maturity, and pulmonary artery medial area thinning may prove beneficial in lessening the severity of the associated pulmonary hypertension in CDH.
Authors:
I Bratu; H Flageole; J M Laberge; M F Chen; B Piedboeuf
Related Documents :
8081899 - Major videothoracoscopic pulmonary resections.
15936539 - Pulmonary function changes after radiotherapy in non-small-cell lung cancer patients wi...
18405129 - Pulmonary manifestations in systemic lupus erythematosus (sle) with special reference t...
3202499 - Lung injury and neutrophil density during air embolization in sheep after leukocyte dep...
19307469 - Nanoparticle-mediated delivery of nuclear factor kappab decoy into lungs ameliorates mo...
19869279 - The effect of multiple emboli of the capillaries and arterioles of one lung.
10661709 - Fatal fungal infection complicating aortic dissection following coronary artery bypass ...
8376289 - Functional evidence for different endothelin receptors in the lung.
2005699 - Clinical significance of intratesticular arterial anatomy.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of pediatric surgery     Volume:  36     ISSN:  0022-3468     ISO Abbreviation:  J. Pediatr. Surg.     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-05-01     Completed Date:  2001-07-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0052631     Medline TA:  J Pediatr Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  739-44     Citation Subset:  IM    
Copyright Information:
Copyright 2001 by W.B. Saunders Company.
Affiliation:
Division of Pediatric Surgery of The Montreal Children's Hospital; the Division of Pathology of The Royal Victoria Hospital, McGill University, Montreal, Quebec; Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anti-Inflammatory Agents / therapeutic use*
Balloon Occlusion / instrumentation,  methods*
Betamethasone / therapeutic use*
Combined Modality Therapy
Disease Models, Animal*
Drug Evaluation, Preclinical
Fetal Diseases / mortality,  therapy*
Fetal Organ Maturity
Gestational Age
Glucocorticoids / therapeutic use*
Hernia, Diaphragmatic / congenital*,  mortality,  therapy*
Humans
Infant, Newborn
Lung / abnormalities*,  drug effects*,  growth & development
Organ Size
Persistent Fetal Circulation Syndrome / mortality,  therapy*
Prenatal Care / methods*
Pulmonary Artery / abnormalities*,  drug effects*,  growth & development
Sheep
Survival Analysis
Trachea*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Glucocorticoids; 378-44-9/Betamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Internal anal sphincter achalasia: outcome after internal sphincter myectomy.
Next Document:  In vivo measurement of intestinal absorption using 3-0 methylglucose in short bowel syndrome.